Next-generation dengue vaccines: Novel strategies currently under development

Viruses

Volumn 3, Issue 10, 2011, Pages 1800-1814

  Durbin, Anna P ^a   Whitehead, Stephen S ^b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Dengue vaccine; DNA vaccine; Sub unit protein vaccine; Vectored vaccine

Indexed keywords

ADENOVIRUS VECTOR; DENGUE VACCINE; DENGUE VIRUS 1 DNA VACCINE; DENGUE VIRUS 1 PRM E DNA VACCINE; DENGUE VIRUS 2 ALPHAVIRUS REPLICON VACCINE; DENGUE VIRUS 2 DNA VACCINE; DENGUE VIRUS 2 E PROTEIN DOMAIN III CARBOXY TERMINAL P64K FUSION PROTEIN; DENGUE VIRUS 2 E PROTEIN DOMAIN III P64K LIPOIL BINDING DOMAIN FUSION PROTEIN; DENGUE VIRUS 2 SUBUNIT 80E PROTEIN VACCINE; DENGUE VIRUS 2 VACCINE; DENGUE VIRUS 3 ALPHAVIRUS REPLICON VACCINE; DENGUE VIRUS 4 VACCINE; DENGUE VIRUS PRM E GLYCOPROTEIN COMPLEX VACCINE; DNA VACCINE; E PROTEIN DOMAIN III VACCINE; FUSION PROTEIN PRM E LYSOSOME ASSOCIATED MEMBRANE DNA VACCINE; GLYCOPROTEIN E; GLYCOPROTEIN PRM; LIVE VACCINE; RECOMBINANT DENGUE VIRUS 1 SUBUNIT 80E PROTEIN VACCINE; RECOMBINANT FUSION PROTEIN DENGUE VIRUS 2 ENVELOPE PROTEIN DOMAIN III MALTOSE BINDING PROTEIN VACCINE; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS GLYCOPROTEIN;

ANTIBODY COMBINING SITE; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; DENGUE; DENGUE VIRUS; DNA SHUFFLING; DOSE RESPONSE; DRUG DEVELOPMENT; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG MIXTURE; DRUG POTENCY; DRUG SCREENING; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; MOLECULAR CLONING; NONHUMAN; PROTEIN DOMAIN; PROTEIN SECRETION; PROTEIN TARGETING; REPLICON; SEROTYPE; SINGLE DRUG DOSE; VACCINATION; VIRUS INTERFERENCE;

DENGUE VACCINE; DNA VACCINE; SUB-UNIT PROTEIN VACCINE; VECTORED-VACCINE;

ANTIGENS, VIRAL; DENGUE; DENGUE VACCINES; DENGUE VIRUS; GENETIC VECTORS; HUMANS; VACCINES, ATTENUATED; VACCINES, DNA; VACCINES, SYNTHETIC; VIRAL INTERFERENCE;

ADENOVIRIDAE; ALPHAVIRUS;

EID: 80054989505     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v3101800     Document Type: Article

References (65)

1. Halstead, S.B.; Vaughn, D.W. Dengue vaccines. In Vaccines, 5th ed.; Plotkin, S., Orenstein, W.A., Offit, P.A., Eds.; Elsevier: Philadelphia PA, USA, 2008, 1155-1162.
2. Beatty, M.; Letson, G.W.; Margolis, H.S. Estimating the global burden of dengue. Am. J. Trop. Med. Hyg. 2009, 81, 231.
3. Burke, D.S.; Nisalak, A.; Johnson, D.E.; Scott, R.M. A prospective study of dengue infections in Bangkok. Am. J. Trop. Med. Hyg. 1988, 38, 172-180.
4. Gibbons, R.V.; Kalanarooj, S.; Jarman, R.G.; Nisalak, A.; Vaughn, D.W.; Endy, T.P.; Mammen, M.P., Jr.; Srikiatkhachorn, A. Analysis of repeat hospital admissions for dengue to estimate the frequency of third or fourth dengue infections resulting in admissions and dengue hemorrhagic fever, and serotype sequences. Am. J. Trop. Med. Hyg. 2007, 77, 910-913.
5. Vaughn, D.W.; Green, S.; Kalayanarooj, S.; Innis, B.L.; Nimmannitya, S.; Suntayakorn, S.; Endy, T.P.; Raengsakulrach, B.; Rothman, A.L.; Ennis, F.A. et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J. Infect. Dis. 2000, 181, 2-9.
6. Sabin, A. Research on dengue during World War II. Am. J. Trop. Med. Hyg. 1952, 1, 30-50.
7. Kaufman, B.M.; Summers, P.L.; Dubois, D.R.; Eckels, K.H. Monoclonal antibodies against dengue 2 virus e-glycoprotein protect mice against lethal dengue infection. Am. J. Trop. Med. Hyg. 1987, 36, 427-434.
8. Kaufman, B.M.; Summers, P.L.; Dubois, D.R.; Cohen, W.H.; Gentry, M.K.; Timchak, R.L.; Burke, D.S.; Eckels, K.H. Monoclonal antibodies for dengue virus prm glycoprotein protect mice against lethal dengue infection. Am. J. Trop. Med. Hyg. 1989, 41, 576-580.
9. Henchal, E.A.; Henchal, L.S.; Schlesinger, J.J. Synergistic interactions of anti-ns1 monoclonal antibodies protect passively immunized mice from lethal challenge with dengue 2 virus. J. Gen. Virol. 1988, 69, 2101-2107.
10. Roehrig, J.T.; Bolin, R.A.; Kelly, R.G. Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica. Virology 1998, 246, 317-328.
11. Guirakhoo, F.; Bolin, R.A.; Roehrig, J.T. The Murray Valley encephalitis virus prm protein confers acid resistance to virus particles and alters the expression of epitopes within the r2 domain of E glycoprotein. Virology 1992, 191, 921-931.
12. Morrison, D.; Legg, T.J.; Billings, C.W.; Forrat, R.; Yoksan, S.; Lang, J. A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults. J. Infect. Dis. 2010, 201, 370-377.
13. Simasathien, S.; Thomas, S.J.; Watanaveeradej, V.; Nisalak, A.; Barberousse, C.; Innis, B.L.; Sun, W.; Putnak, J.R.; Eckels, K.H.; Hutagalung, Y. et al. Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children. Am. J. Trop. Med. Hyg. 2008, 78, 426-433.
14. Sun, W.; Cunningham, D.; Wasserman, S.S.; Perry, J.; Putnak, J.R.; Eckels, K.H.; Vaughn, D.W.; Thomas, S.J.; Kanesa-Thasan, N.; Innis, B.L. et al. Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naive adults. Hum. Vaccin. 2009, 5, 33-40.
15. Kanesa-thasan, N.; Sun, W.; Kim-Ahn, G.; Van Albert, S.; Putnak, J.R.; King, A.; Raengsakulsrach, B.; Christ-Schmidt, H.; Gilson, K.; Zahradnik, J.M. et al. Safety and immunogenicity of attenuated dengue virus vaccines (aventis pasteur) in human volunteers. Vaccine 2001, 19, 3179-3188.
16. Sabchareon, A.; Lang, J.; Chanthavanich, P.; Yoksan, S.; Forrat, R.; Attanath, P.; Sirivichayakul, C.; Pengsaa, K.; Pojjaroen-Anant, C.; Chambonneau, L. et al. Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old thai children. Pediatr. Infect. Dis. J. 2004, 23, 99-109.
17. Guirakhoo, F.; Pugachev, K.; Zhang, Z.; Myers, G.; Levenbook, I.; Draper, K.; Lang, J.; Ocran, S.; Mitchell, F.; Parsons, M. et al. Safety and efficacy of chimeric yellow fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J. Virol. 2004, 78, 4761-4775.
18. Poo, J.; Galan, F.; Forrat, R.; Zambrano, B.; Lang, J.; Dayan, G.H. Live-attenuated tetravalent dengue vaccine in dengue-naive children, adolescents, and adults in Mexico city: Randomized controlled phase 1 trial of safety and immunogenicity. Pediatr. Infect. Dis. J. 2011, 30, e9-e17.
19. Capeding, R.Z.; Luna, I.A.; Bomasang, E.; Lupisan, S.; Lang, J.; Forrat, R.; Wartel, A.; Crevat, D. Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: Randomized controlled phase I trial in the Philippines. Vaccine 2011, 29, 3863-3872.
20. Durbin, A.P.; Whitehead, S.S. Dengue vaccine candidates in development. Curr. Top. Microbiol. Immunol. 2010, 338, 129-143.
21. Whitehead, S.S.; Durbin, A.P. Prospects and challenges for dengue virus vaccine development. In Frontiers in Dengue Virus Research; Hanley, K.A., Weaver, S.C., Eds.; Caister Academic Press: Portland, OR, USA, 2010.
22. Guy, B.; Barban, V.; Mantel, N.; Aguirre, M.; Gulia, S.; Pontvianne, J.; Jourdier, T.M.; Ramirez, L.; Gregoire, V.; Charnay, C. et al. Evaluation of interferences between dengue vaccine serotypes in a monkey model. Am. J. Trop. Med. Hyg. 2009, 80, 302-311.
23. Kitchener, S.; Nissen, M.; Nasveld, P.; Forrat, R.; Yoksan, S.; Lang, J.; Saluzzo, J.F. Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults. Vaccine 2006, 24, 1238-1241.
24. Moss, B. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc. Natl. Acad. Sci. U. S. A. 1996, 93, 11341-11348.
25. Liniger, M.; Zuniga, A.; Naim, H.Y. Use of viral vectors for the development of vaccines. Expet Rev. Vaccine. 2007, 6, 255-266.
26. Catanzaro, A.T.; Koup, R.A.; Roederer, M.; Bailer, R.T.; Enama, M.E.; Moodie, Z.; Gu, L.; Martin, J.E.; Novik, L.; Chakrabarti, B.K. et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J. Infect. Dis. 2006, 194, 1638-1649.
27. Kochel, T.; Wu, S.J.; Raviprakash, K.; Hobart, P.; Hoffman, S.; Porter, K.; Hayes, C. Inoculation of plasmids expressing the dengue-2 envelope gene elicit neutralizing antibodies in mice. Vaccine 1997, 15, 547-552.
28. Simmons, M.; Murphy, G.S.; Hayes, C.G. Short report: Antibody responses of mice immunized with a tetravalent dengue recombinant protein subunit vaccine. Am. J. Trop. Med. Hyg. 2001, 65, 159-161.
29. Simmons, M.; Murphy, G.S.; Kochel, T.; Raviprakash, K.; Hayes, C.G. Characterization of antibody responses to combinations of a dengue-2 DNA and dengue-2 recombinant subunit vaccine. Am. J. Trop. Med. Hyg. 2001, 65, 420-426.
30. Porter, K.R.; Kochel, T.J.; Wu, S.J.; Raviprakash, K.; Phillips, I.; Hayes, C.G. Protective efficacy of a dengue 2 DNA vaccine in mice and the effect of cpg immuno-stimulatory motifs on antibody responses. Arch. Virol. 1998, 143, 997-1003.
31. Raviprakash, K.; Marques, E.; Ewing, D.; Lu, Y.; Phillips, I.; Porter, K.R.; Kochel, T.J.; August, T.J.; Hayes, C.G.; Murphy, G.S. Synergistic neutralizing antibody response to a dengue virus type 2 DNA vaccine by incorporation of lysosome-associated membrane protein sequences and use of plasmid expressing gm-csf. Virology 2001, 290, 74-82.
32. Lu, Y.; Raviprakash, K.; Leao, I.C.; Chikhlikar, P.R.; Ewing, D.; Anwar, A.; Chougnet, C.; Murphy, G.; Hayes, C.G.; August, T.J. et al. Dengue 2 prem-e/lamp chimera targeted to the mhc class ii compartment elicits long-lasting neutralizing antibodies. Vaccine 2003, 21, 2178-2189.
33. Raviprakash, K.; Kochel, T.J.; Ewing, D.; Simmons, M.; Phillips, I.; Hayes, C.G.; Porter, K.R. Immunogenicity of dengue virus type 1 DNA vaccines expressing truncated and full length envelope protein. Vaccine 2000, 18, 2426-2434.
34. Raviprakash, K.; Porter, K.R.; Kochel, T.J.; Ewing, D.; Simmons, M.; Phillips, I.; Murphy, G.S.; Weiss, W.R.; Hayes, C.G. Dengue virus type 1 DNA vaccine induces protective immune responses in rhesus macaques. J. Gen. Virol. 2000, 81, 1659-1667.
35. Kochel, T.J.; Raviprakash, K.; Hayes, C.G.; Watts, D.M.; Russell, K.L.; Gozalo, A.S.; Phillips, I.A.; Ewing, D.F.; Murphy, G.S.; Porter, K.R. A dengue virus serotype-1 DNA vaccine induces virus neutralizing antibodies and provides protection from viral challenge in aotus monkeys. Vaccine 2000, 18, 3166-3173.
36. Raviprakash, K.; Ewing, D.; Simmons, M.; Porter, K.R.; Jones, T.R.; Hayes, C.G.; Stout, R.; Murphy, G.S. Needle-free biojector injection of a dengue virus type 1 DNA vaccine with human immunostimulatory sequences and the gm-csf gene increases immunogenicity and protection from virus challenge in aotus monkeys. Virology 2003, 315, 345-352.
37. Beckett, C.G.; Tjaden, J.; Burgess, T.; Danko, J.R.; Tamminga, C.; Simmons, M.; Wu, S.J.; Sun, P.; Kochel, T.; Raviprakash, K. et al. Evaluation of a prototype dengue-1 DNA vaccine in a phase 1 clinical trial. Vaccine 2011, 29, 960-968.
38. Konishi, E.; Yamaoka, M.; Kurane, I.; Mason, P.W. A DNA vaccine expressing dengue type 2 virus premembrane and envelope genes induces neutralizing antibody and memory b cells in mice. Vaccine 2000, 18, 1133-1139.
39. Konishi, E.; Kosugi, S.; Imoto, J. Dengue tetravalent DNA vaccine inducing neutralizing antibody and anamnestic responses to four serotypes in mice. Vaccine 2006, 24, 2200-2207.
40. Imoto, J.; Konishi, E. Dengue tetravalent DNA vaccine increases its immunogenicity in mice when mixed with a dengue type 2 subunit vaccine or an inactivated Japanese encephalitis vaccine. Vaccine 2007, 25, 1076-1084.
41. Apt, D.; Raviprakash, K.; Brinkman, A.; Semyonov, A.; Yang, S.; Skinner, C.; Diehl, L.; Lyons, R.; Porter, K.; Punnonen, J. Tetravalent neutralizing antibody response against four dengue serotypes by a single chimeric dengue envelope antigen. Vaccine 2006, 24, 335-344.
42. Raviprakash, K.; Apt, D.; Brinkman, A.; Skinner, C.; Yang, S.; Dawes, G.; Ewing, D.; Wu, S.J.; Bass, S.; Punnonen, J. et al. A chimeric tetravalent dengue DNA vaccine elicits neutralizing antibody to all four virus serotypes in rhesus macaques. Virology 2006, 353, 166-173.
43. Holman, D.H.; Wang, D.; Raviprakash, K.; Raja, N.U.; Luo, M.; Zhang, J.; Porter, K.R.; Dong, J.Y. Two complex, adenovirus-based vaccines that together induce immune responses to all four dengue virus serotypes. Clin. Vaccine Immunol. 2007, 14, 182-189.
44. Raja, N.U.; Holman, D.H.; Wang, D.; Raviprakash, K.; Juompan, L.Y.; Deitz, S.B.; Luo, M.; Zhang, J.; Porter, K.R.; Dong, J.Y. Induction of bivalent immune responses by expression of dengue virus type 1 and type 2 antigens from a single complex adenoviral vector. Am. J. Trop. Med. Hyg. 2007, 76, 743-751.
45. Raviprakash, K.; Wang, D.; Ewing, D.; Holman, D.H.; Block, K.; Woraratanadharm, J.; Chen, L.; Hayes, C.; Dong, J.Y.; Porter, K. A tetravalent dengue vaccine based on a complex adenovirus vector provides significant protection in rhesus monkeys against all four serotypes of dengue viruses. J. Virol. 2008, 82, 6927-6934.
46. Khanam, S.; Rajendra, P.; Khanna, N.; Swaminathan, S. An adenovirus prime/plasmid boost strategy for induction of equipotent immune responses to two dengue virus serotypes. BMC Biotechnol. 2007, 7, 10.
47. White, L.J.; Parsons, M.M.; Whitmore, A.C.; Williams, B.M.; de Silva, A.; Johnston, R.E. An immunogenic and protective alphavirus replicon particle-based dengue vaccine overcomes maternal antibody interference in weanling mice. J. Virol. 2007, 81, 10329-10339.
48. White, L.J.; Yingsiwaphat, V.; Wahala, W.; Parsons, M.M.; Fuller, L.; Collier, M.; Sariol, C.A.; de Silva, A. An alphavirus replicon based dengue vaccine is immunogenic and protective in rhesus macaques and induces predominantly domain iii reactive neutralizing antibodies. In Proceedings of The American Society of Tropical Medicine and Hygiene 59th Annual Meeting, American Society of Tropical Medicine and Hygiene, Atlanta, GA, USA, 2010; Volume 83, p. 246.
49. Putnak, J.R.; Coller, B.A.; Voss, G.; Vaughn, D.W.; Clements, D.; Peters, I.; Bignami, G.; Houng, H.S.; Chen, R.C.; Barvir, D.A. et al. An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model. Vaccine 2005, 23, 4442-4452.
50. Clements, D.E.; Coller, B.A.; Lieberman, M.M.; Ogata, S.; Wang, G.; Harada, K.E.; Putnak, J.R.; Ivy, J.M.; McDonell, M.; Bignami, G.S. et al. Development of a recombinant tetravalent dengue virus vaccine: Immunogenicity and efficacy studies in mice and monkeys. Vaccine 2010, 28, 2705-2715.
51. Hermida, L.; Bernardo, L.; Martin, J.; Alvarez, M.; Prado, I.; Lopez, C.; Sierra Bde, L.; Martinez, R.; Rodriguez, R.; Zulueta, A. et al. A recombinant fusion protein containing the domain iii of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates. Vaccine 2006, 24, 3165-3171.
52. Valdes, I.; Bernardo, L.; Gil, L.; Pavon, A.; Lazo, L.; Lopez, C.; Romero, Y.; Menendez, I.; Falcon, V.; Betancourt, L. et al. A novel fusion protein domain iii-capsid from dengue-2, in a highly aggregated form, induces a functional immune response and protection in mice. Virology 2009, 394, 249-258.
53. Valdes, I.; Gil, L.; Romero, Y.; Castro, J.; Puente, P.; Lazo, L.; Marcos, E.; Guzman, M.G.; Guillen, G.; Hermida, L. The chimeric protein domain iii-capsid of dengue virus serotype 2 (den-2) successfully boosts neutralizing antibodies generated in monkeys upon infection with den-2. Clin. Vaccine Immunol. 2011, 18, 455-459.
54. Valdes, I.; Hermida, L.; Martin, J.; Menendez, T.; Gil, L.; Lazo, L.; Castro, J.; Niebla, O.; Lopez, C.; Bernardo, L. et al. Immunological evaluation in nonhuman primates of formulations based on the chimeric protein p64k-domain iii of dengue 2 and two components of neisseria meningitidis. Vaccine 2009, 27, 995-1001.
55. Santra, S.; Seaman, M.S.; Xu, L.; Barouch, D.H.; Lord, C.I.; Lifton, M.A.; Gorgone, D.A.; Beaudry, K.R.; Svehla, K.; Welcher, B. et al. Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates. J. Virol. 2005, 79, 6516-6522.
56. Barouch, D.H.; Nabel, G.J. Adenovirus vector-based vaccines for human immunodeficiency virus type 1. Hum. Gene Ther. 2005, 16, 149-156.
57. Sullivan, N.J.; Sanchez, A.; Rollin, P.E.; Yang, Z.Y.; Nabel, G.J. Development of a preventive vaccine for ebola virus infection in primates. Nature 2000, 408, 605-609.
58. Jaiswal, S.; Khanna, N.; Swaminathan, S. Replication-defective adenoviral vaccine vector for the induction of immune responses to dengue virus type 2. J. Virol. 2003, 77, 12907-12913.
59. MacDonald, G.H.; Johnston, R.E. Role of dendritic cell targeting in venezuelan equine encephalitis virus pathogenesis. J. Virol. 2000, 74, 914-922.
60. Thompson, J.M.; Whitmore, A.C.; Konopka, J.L.; Collier, M.L.; Richmond, E.M.; Davis, N.L.; Staats, H.F.; Johnston, R.E. Mucosal and systemic adjuvant activity of alphavirus replicon particles. Proc. Natl. Acad. Sci. U. S. A. 2006, 103, 3722-3727.
61. Coller, B.A.; Clements, D.; Ogata, S.; Martyak, T.; Thorne, M.; Yelmene, M.; Parks, E. Clinical development of a recombinant subunit vaccine for dengue. In Proceedings of the American Society of Tropical Medicine and Hygiene 59th Annual Meeting, Atlanta, GA, USA, 4-7 November 2010; p. 248.
62. Zhang, W.; Chipman, P.R.; Corver, J.; Johnson, P.R.; Zhang, Y.; Mukhopadhyay, S.; Baker, T.S.; Strauss, J.H.; Rossmann, M.G.; Kuhn, R.J. Visualization of membrane protein domains by cryo-electron microscopy of dengue virus. Nat. Struct. Biol. 2003, 10, 907-912.
63. Roehrig, J.T. Antigenic structure of flavivirus proteins. Adv. Virus Res. 2003, 59, 141-175.
64. Crill, W.D.; Roehrig, J.T. Monoclonal antibodies that bind to domain iii of dengue virus e glycoprotein are the most efficient blockers of virus adsorption to vero cells. J. Virol. 2001, 75, 7769-7773.
65. Hermida, L.; Rodriguez, R.; Lazo, L.; Silva, R.; Zulueta, A.; Chinea, G.; Lopez, C.; Guzman, M.G.; Guillen, G. A dengue-2 envelope fragment inserted within the structure of the p64k meningococcal protein carrier enables a functional immune response against the virus in mice. J. Virol. Methods 2004, 115, 41-49.